Cost/success projections for US biodefense countermeasure development
Nature biotechnology, vol. 26, no. 9, 2008, pp. 981–983
Abstract
A survey of the pipeline of drugs and vaccines in clinical development that can fulfill HHS biodefense medical countermeasure requirements shows that, based on historical data of biopharmaceutical development, the funding allocations for clinical development of biodefense MCMs have direct impacts on the probability of successfully satisfying PHEMCE requirements. The US government must decide what probability of failure it is willing to tolerate and make the associated commitment to MCM development. – AI-generated abstract.
